This independent meeting was supported and funded by the following pharmaceutical companies: A Menarini Farmaceutica UK Ltd, Astellas Pharma Ltd, AstraZeneca UK Ltd, Bayer plc, CSL Vifor, GSK, Novo Nordisk Ltd, and Sanofi.
The meeting promoted and shared academic interest across the cardiorenal spectrum of disease taking in new targets, treatments and technologies in diabetes, heart failure, kidney transplantation, and chronic kidney disease.
Watch our state-of-the-art presentations with interactive discussion and case-based learning given by our expert faculty. Please note: CPD credits are no longer available.
Session 6 is unavailable.
Is it for me?
These videos are for healthcare professionals only and are aimed at anyone treating the cardiorenal patient particularly those working in heart failure, cardiology, nephrology, diabetes, lipids, endocrinology, care of the elderly, general medicine, general practice, clinical pharmacy and allied disciplines.
Feedback from past delegates has been very positive with 98% of delegates at our last meeting saying the meeting was clinically excellent or good.
Academic endorsement
This year’s meeting has been endorsed by The British Society for Heart Failure (BSH), the Irish Nephrology Society, Kidney Disease Improving Global Outcomes (KDIGO), and the UK Kidney Association (UKKA).
Chair: Professor Philip Kalra, Consultant Nephrologist, Salford Royal NHS Foundation Trust; Professor of Renal Medicine, University of Manchester | |
Effects of live-donor nephrectomy on cardiovascular function Dr Anna Price, Specialist Registrar in Renal Medicine, Queen Elizabeth University Hospital, Birmingham | |
What’s new in advanced heart failure care (mechanical circulatory support, and cardiac transplantation) and when to consider it Dr Jayan Parameshwar, Consultant Cardiologist, Royal Papworth Hospital NHS Foundation Trust, Cambridge | |
Discussion |
Chair: Dr Caroline Day, Visiting Fellow, School of Life and Health Sciences, Aston University, Birmingham | |
Diabetes guidelines: choosing the right drugs for the right patients Professor Cliff Bailey, Emeritus Professor, School of Life and Health Sciences, Aston University, Birmingham | |
Weight loss to improve microvascular function Dr Safwaan Adam, Consultant Endocrinologist, The Christie NHS Foundation Hospital, Manchester | |
Discussion |
Chair: Professor Paul Kalra, Consultant Cardiologist, Portsmouth Hospitals University NHS Trust | |
Iron deficiency anaemia – rationale for studies in cardiorenal patients Dr Sharlene Greenwood, President, UK Kidney Association; NIHR Advanced Research Fellow, and Consultant Physiotherapist, King’s College Hospital, London | |
Hypoxia-inducible factor stabilisers (HIF) in renal anaemia Professor Jonathan Barratt, The Mayer Professor of Renal Medicine, University of Leicester | |
Discussion |
Chair: Professor Smeeta Sinha, Consultant Nephrologist, Salford Royal NHS Foundation Trust | |
Speakers Dr Luis Lopes, Consultant Cardiologist, Barts Health NHS Trust, London Dr Shabbir Moochhala, Consultant Nephrologist, Royal Free Hospital, London |
|
Chairs: Dr Lisa Anderson, Heart Failure Consultant, Cardiovascular Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London | |
Diabetic cardiomyopathy – advances in understanding Professor Gerry McCann, NIHR Research Professor (Experimental Medicine) and Professor of Cardiac Imaging, University of Leicester | |
Discussion |
Chair: Professor Derek Yellon, Professor of Molecular and Cellular Cardiology, University College London; Director of the Hatter Cardiovascular Institute, London | |
Cardiology trials update Dr Geraint Morton, Consultant Cardiologist, Portsmouth Hospitals University NHS Trust | |
Renal trials update Dr David Lappin, Consultant Nephrologist and General Physician, Galway University Hospitals | |
Discussion |
Chair: TBC | |
The need for an MDT (and teasing out ‘unknown CKD’) Professor Smeeta Sinha, Consultant Nephrologist, Salford Royal NHS Foundation Trust; Honorary Lecturer, University of Manchester | |
Discussion |
Moderators: Dr Sarah Birkhoelzer, Cardiology Registrar, Radcliffe Department of Medicine, Oxford; Professor Paul Kalra, Consultant Cardiologist, Portsmouth Hospitals University NHS Trust; Professor Philip Kalra, Consultant Nephrologist, Salford Royal NHS Foundation Trust; Professor of Renal Medicine, University of Manchester | |
Case 1: Anticoagulation in CKD Miss Kathrine Parker, Specialist Renal Pharmacist and NIHR Clinical Doctoral Fellow, Manchester University NHS Foundation Trust | |
Case 2: Dyslipidaemia in high-risk patients – new treatment options Dr Wei Yang, Registrar in Metabolic Medicine, Imperial College London | |
Case 3: Finerenone in CKD Dr Kieran McCafferty, Consultant Nephrologist, Barts Health NHS Trust, London | |
Summing up |
Dr Safwaan Adam |
|
Dr Lisa Anderson |
|
Professor Cliff Bailey |
|
Professor Jonathan Barratt |
|
Dr Sarah Birkhoelzer |
|
Dr Caroline Day |
|
Dr Sharlene Greenwood |
|
Professor Paul Kalra |
|
Professor Philip Kalra |
|
Dr David Lappin |
Dr Luis Lopes |
|
Dr Kieran McCafferty |
|
Professor Gerry McCann |
|
Dr Shabbir Moochhala |
|
Dr Geraint Morton |
|
Dr Jayan Parameshwar |
|
Miss Kathrine Parker |
|
Dr Anna Price |
|
Professor Smeeta Sinha |
|
Dr Wei Yang Registrar in Metabolic Medicine, Imperial College London |
|
Professor Derek Yellon |
This independent meeting is being supported and funded by pharmaceutical companies including A Menarini Farmaceutica UK Ltd, Astellas Pharma Ltd, AstraZeneca UK Ltd, Bayer plc, CSL Vifor, GSK, Novo Nordisk Ltd, and Sanofi. This has enabled us to offer a subsidised registration fee.
For details of sponsorship packages available, please contact info@cardiorenalforum.com